Factor V Leiden is not common in patients diagnosed with primary pulmonary hypertension

European Respiratory Journal

Volumn 12, Issue 5, 1998, Pages 1177-1180

  Elliott, C G ^a,c   Leppert, M F ^a   Alexander, G J ^a   Ward, K ^a   Nelson, L ^a   Pietra, G G ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LDS HOSPITAL   (United States)

Author keywords

Factor V Leiden; Primary pulmonary hypertension

Indexed keywords

ACTIVATED PROTEIN C; ADENINE; BLOOD CLOTTING FACTOR 5; DNA; GUANINE; NUCLEOTIDE;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; LUNG ARTERY PRESSURE; LUNG PERFUSION; LUNG TRANSPLANTATION; MALE; MICROCIRCULATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; THROMBOSIS;

EID: 0031761056     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.12051177     Document Type: Article

References (28)

1. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension: clinical and hemodynamic study. Am J Med 1951; 11: 686-705.
2. Rich S, Dantzger DR, Ayres SM, et al. Primary pulmonary hypertension (A National Prospective Study). Ann Intern Med 1987; 107: 216-223.
3. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
4. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198-1206.
5. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 1959; 21: 557-570.
6. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
7. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-2138.
8. Chaouat A, Weitzenblum E. Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Enr Respir J 1996; 9: 356-363.
9. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110: 710-717.
10. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42: 1163-1181.
11. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
12. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990; 82: 841-847.
13. Rich S, Pietra GG, Kieras K, Hart K, Brundage BH. Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med 1986; 105: 497-502.
14. Geggel RL, Carvalho AC, Hoyer LW, Reid LM. Von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis 1987; 135: 294-299.
15. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
16. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
17. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
18. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
19. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
20. Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2802.
21. Vandenbrouke JP, Koster T, Briet E, Rietsma PH, Bertina R, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
22. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden - effect on thrombosis. N Engl J Med 1996; 334: 763-768.
23. Ridker PM, Hennekens CH, Miletich JP, Buring JE. Ethnic distribution of activated protein C resistance among American women. Circulation 1996; 94: (Suppl.) 0065.
24. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
25. Arruda VR, Annichino-Bissacchi JM, Costa FF, Reitsma PH. Factor V Leiden (FVQ 506) is common in a Brazilian population. Am J Hematol 1995; 49: 242-243.
26. Rosendaal FR, Koster T, Vandenbroucke JP, Rietsma PH. High-risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508.
27. Loyd JE, Atkinson JB, Pietra GG, Virmani R, Newman JH. Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. Am Rev Respir Dis 1988; 138: 952-957.
28. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985; 60: 16-25.